⚕ GalenOps CRO console
← 709 (USA)

709-1306

completed
Study: Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease. Phase II · Site: 709 (USA) (Dr. Novak) · consented 2014-02-03
Adverse events
9
Serious AEs
0
Open data queries
0
Luna dropout signal
–

Adverse events

moderate assessed 2026-08-18

Moderate APPLICATION SITE IRRITATION — outcome: NOT RECOVERED/NOT RESOLVED; onset 2014-05-04 (study day 91.0); relationship: PROBABLE

moderate assessed 2026-08-18

Moderate APPLICATION SITE IRRITATION — outcome: RECOVERED/RESOLVED; onset 2014-05-04 (study day 91.0); relationship: PROBABLE

mild assessed 2026-08-18

Mild APPLICATION SITE PRURITUS — outcome: NOT RECOVERED/NOT RESOLVED; onset 2014-04-20 (study day 77.0); relationship: PROBABLE

moderate assessed 2026-08-18

Moderate APPLICATION SITE PRURITUS — outcome: NOT RECOVERED/NOT RESOLVED; onset 2014-04-20 (study day 77.0); relationship: PROBABLE

moderate assessed 2026-08-18

Moderate APPLICATION SITE PRURITUS — outcome: RECOVERED/RESOLVED; onset 2014-04-20 (study day 77.0); relationship: PROBABLE

mild assessed 2026-08-18

Mild DRUG ERUPTION — outcome: RECOVERED/RESOLVED; onset 2014-05-20 (study day 107.0); relationship: NONE

mild assessed 2026-08-18

Mild RASH — outcome: NOT RECOVERED/NOT RESOLVED; onset 2014-04-20 (study day 77.0); relationship: PROBABLE

moderate assessed 2026-08-18

Moderate RASH — outcome: NOT RECOVERED/NOT RESOLVED; onset 2014-04-20 (study day 77.0); relationship: PROBABLE

moderate assessed 2026-08-18

Moderate RASH — outcome: RECOVERED/RESOLVED; onset 2014-04-20 (study day 77.0); relationship: PROBABLE

Data queries

No data queries.

☾ Luna engagement

This participant doesn't use Luna.